Lv21
150 积分 2024-10-23 加入
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
2小时前
待确认
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
3小时前
已完结
Enhancing the bystander effect of antibody-drug conjugate by using a novel caspase-3 cleavable peptide linker to overcome tumor heterogeneity
2个月前
已完结
Prognostic value of [18F]FDG PET/CT parameters in surgically resected primary lung adenocarcinoma: a single-center experience
4个月前
已完结
Evaluation of Tumor Measurements in Oncology: Use of Film-Based and Electronic Techniques
4个月前
已关闭
Patient-derived Tumour Organoids: A Bridge between Cancer Biology and Personalised Therapy
4个月前
已完结
Plasma Protein Binding as an Optimizable Parameter for In Vivo Efficacy
4个月前
已完结
EP.03F.03 Orally Bioavailable Cyclin A/B Rxl Macrocycle has Antitumor Effect in SCLC & NSCLC Cell Line Derived (CDX) & Patient Derived Xenograft (PDX) Models
6个月前
已关闭
Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients
7个月前
已完结
Alzheimer’s Disease: Pathogenesis and Therapeutic Interventions
9个月前
已完结
皖公网安备34019202002308
